TheraCryf (FRA:8EV) COGS-to-Revenue : 0.00 (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is TheraCryf COGS-to-Revenue?

TheraCryf's Cost of Goods Sold for the six months ended in Sep. 2023 was €0.00 Mil. Its Revenue for the six months ended in Sep. 2023 was €0.46 Mil.

TheraCryf's COGS to Revenue for the six months ended in Sep. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. TheraCryf's Gross Margin % for the six months ended in Sep. 2023 was N/A%.

TheraCryf COGS-to-Revenue Historical Data

The historical data trend for TheraCryf's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf COGS-to-Revenue Chart

TheraCryf Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

COGS-to-Revenue

Get a 7-Day Free Trial

TheraCryf Semi-Annual Data
	Mar13	Mar14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

TheraCryf COGS-to-Revenue Calculation

TheraCryf's COGS to Revenue for the fiscal year that ended in Mar. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.501
	=	0.00

TheraCryf's COGS to Revenue for the quarter that ended in Sep. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.459
	=	0.00

TheraCryf (FRA:8EV) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

TheraCryf's Gross Margin % for the six months ended in Sep. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0.459
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

TheraCryf COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of TheraCryf's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

TheraCryf (FRA:8EV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (FRA:8EV) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

EVG:UK

Address

Congleton Road, Suite 24G13- Block 24, Alderley Park, Nether Alderley, GBR, SK10 4TG

Website

https://www.evgen.com

Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.

TheraCryf (FRA:8EV) Headlines

No Headlines